It's a glorious time to be alive for Maya Jama and Stormzy fans, as the power couple have just provided more evidence that they're back together and stronger than ever
Love Island presenter Maya Jama and BRIT Award winning musician Stormzy were first linked back in 2015, and subsequently went on to date for four years.
However, to the dismay of fans everywhere, Maya and Stormzy decided to call it quits in 2019. It was speculated that the split was down to work pressures, with both wanting to focus on their growing careers. While speculation that they're back together has been circulating for a while now - they were spotted holding hands while on holiday in Greece last month - Maya's latest social media post seems to have confirmed everything.
The footage began with Stormzy standing in front of a bright yellow car while holding up and waving two homemade signs. As Maya moved closer, fans could easily read the message on the right, which read: "Maya Jama #1 fan."
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Stormzy and adidas announce #Merky FC expansion to fight lack of diversity in the football industry as new report reveals incredible effect the initiative could have in five yearsGOAL has teamed up with Stormzy and adidas again as they expand Merky FC to give more young black people a chance to work in football.
続きを読む »
Study shows psychotropic medication use has increased in children, teens with type 1 diabetesDispensing of psychotropic medication increased among children and adolescents with type 1 diabetes (T1D) from 2006 to 2019, according to a study published online Oct. 3 in JAMA Network Open.
続きを読む »
GLP-1 weight loss drugs linked to heightened GI risks, says new studyitemprop=description content=Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.
続きを読む »
Adding tirzepatide to basal insulin cuts HbA1c levels in people with poorly controlled type 2 diabetesA team of medical researchers affiliated with multiple institutions in the U.S. working with a colleague from Spain has found via clinical trial that adding tirzepatide (brand name Mounjaro) to basal insulin therapies can reduce HbA1c levels in people with poorly controlled type 2 diabetes. In their paper published in the journal JAMA, the group describes the parameters of the clinical trial and what they learned from it.
続きを読む »